Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 36% Improvement Relative Risk Siraj et al. Famotidine for COVID-19 LATE TREATMENT Is late treatment with famotidine beneficial for COVID-19? Retrospective 1,000 patients in India (March - December 2020) Lower mortality with famotidine (p=0.0016) Siraj et al., Indian J. Clinical Practice, 32:9 Favors famotidine Favors control
Efficacy of Various Treatment Modalities on Patient-related Outcome in Hospitalized COVID-19 Patients – A Retrospective Study
Siraj et al., Indian Journal of Clinical Practice, 32:9
Siraj et al., Efficacy of Various Treatment Modalities on Patient-related Outcome in Hospitalized COVID-19 Patients – A.., Indian Journal of Clinical Practice, 32:9
Feb 2022   Source   PDF  
  All Studies   Meta
Retrospective 1,000 COVID+ hospitalized patients in India, showing lower mortality with famotidine and remdesivir in multivariable logistic regression.
This study includes remdesivir and famotidine.
risk of death, 36.2% lower, RR 0.64, p = 0.002, treatment 183 of 711 (25.7%), control 122 of 289 (42.2%), NNT 6.1, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Siraj et al., 28 Feb 2022, retrospective, India, peer-reviewed, median age 56.0, 13 authors, study period March 2020 - December 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFamotidineAll
Medicine ^Assistant Professor ¶ Additional Professor ⇑ Professor Dept. of Rheumatology ψ Professor φ Professor and Head
Dr Farhana Siraj, Nazia Mehfooz, Suhail Mantoo, Afshan Shabir, SYED MUDASIR QADRI ¥ , UMAR HAFIZ £ Tajamul Hussain #, Ajaz Nabi Koul
Background: The outbreak of coronavirus disease 2019 (COVID-19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in China, in December 2019, and was declared a pandemic by WHO on March 11, 2020. The treatment is evolving and is mostly supportive in nature. Material and methods: This was a single-center retrospective study that included confirmed COVID-19 cases treated at our institute (a tertiary care hospital in Jammu and Kashmir, India), between March 2020 and December 2020. Patients with age more than 18 years were included in the study. Results: On evaluating the effect of various drug therapies used in management of COVID-19 patients of all severity, use of remdesivir and famotidine was associated with significantly higher odds of survival. In subgroup of patients with severe disease, use of systemic steroids was associated with significantly higher odds of survival in addition to remdesivir and famotidine. In patients with severe COVID-19 illness, likelihood of survival was significantly higher in those who received combination of systemic steroids plus remdesivir compared to steroids and remdesivir alone. Conclusion: Steroids were effective in severe COVID-19 illness and the combination of steroids and remdesivir was more effective in severe illness. There is a need to undertake more large scale prospective randomized trials to determine the most effective drug therapies to treat the sick patients and prevent worsening of mild cases.
Beigel, Tomashek, Dodd, Mehta, Zingman et al., ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 -Final report, N Engl J Med
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19, N Engl J Med
Freedberg, Conigliaro, Wang, Tracey, Callahan et al., Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study, Gastroenterology
Garibaldi, Wang, Robinson, Zeger, Bandeen-Roche et al., Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19, JAMA Netw Open
Guan, Ni, Hu, Liang, Ou et al., China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Hermine, Tharaux, Resche-Rigon, Porcher, Ravaud et al., Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial, JAMA Intern Med
Horby, Pessoa-Amorim, Peto, Brightling, Sarkar et al., Tocilizumab in patients admitted to hospital with COVID-19, RECOVERY
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Janowitz, Gablenz, Pattinson, Wang, Conigliaro et al., Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut
Lee, Chan, Hui, Ng, Wu et al., Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients, J Clin Virol
Lee, Mcdonald, Butler-Laporte, Harrison, Cheng et al., Remdesivir and systemic corticosteroids for the treatment of COVID-19: a Bayesian re-analysis, Int J Infect Dis
Mather, Seip, Mckay, Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19, Am J Gastroenterol
Misra, Nath, Hadda, Vibha, Efficacy of various treatment modalities for nCOV-2019: a systematic review and meta-analysis, Eur J Clin Invest
Pan, Peto, Henao-Restrepo, Preziosi, Sathiyamoorthy et al., Repurposed antiviral drugs for Covid-19--Interim WHO Solidarity Trial Results, N Engl J Med
Recovery Collaborative Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in hospitalized patients with Covid-19, N Engl J Med
Recovery Collaborative Group, Horby, Mafham, Linsell, Bell et al., Effect of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Rubin, Longo, Baden, Interleukin-6 receptor inhibition in Covid-19 -Cooling the inflammatory soup, N Engl J Med
Ruiz-Irastorza, Pijoan, Bereciartua, Dunder, Dominguez et al., Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: an observational comparative study using routine care data, PLoS One
Salama, Han, Yau, Reiss, Kramer et al., Tocilizumab in patients hospitalized with Covid-19 Pneumonia, N Engl J Med
Soin, Kumar, Choudhary, Sharma, Mehta et al., Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial, Lancet Respir Med
Spinner, Gottlieb, Criner, López, Cattelan et al., Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA
Tang, Feng, Ni, Zhang, Liu et al., Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial, Respiration
Van Paassen, Vos, Hoekstra, Neumann, Boot et al., Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes, Crit Care
Villar, Ferrando, Martínez, Ambrós, Muñoz et al., Dexamethasone in ARDS Network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial, Lancet Respir Med
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Wu, Liu, Yang, Zhang, Zhong et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop